Equillium (EQ) Osake Kurssi

Equillium Inc primarily operates in the biotechnology and pharmaceutical industries.

Some of the main competitors of Equillium Inc in the market include other biopharmaceutical companies focusing on developing novel therapies for autoimmune and inflammatory diseases. These competitors may include companies such as AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, and Johnson & Johnson.

Equillium Inc is a clinical stage biotechnology company. Founded in 2017, the company aims to develop innovative therapies for severe autoimmune and inflammatory disorders. Equillium focuses on targeting the CD6-ALCAM pathway, which plays a crucial role in regulating the immune system. By inhibiting this pathway, Equillium seeks to address diseases such as acute graft-versus-host disease (aGVHD) and uncontrolled asthma. The company's dedication to scientific excellence and collaboration with leading researchers and clinicians positions Equillium as a promising player in the biotech industry. Equillium Inc's commitment to advancing novel treatments for debilitating conditions sets it apart in the field of immunotherapy.

Equillium Inc has achieved significant milestones in its company history. The company successfully initiated its Phase 1b clinical trial for its leading product candidate, EQ001, in patients with asthma in 2018. In 2019, Equillium announced positive results from its Phase 1b trial, showcasing the potential of EQ001 in treating patients with moderate-to-severe asthma. Additionally, Equillium initiated a Phase 1 trial for its second product candidate, EQ002, in patients with chronic graft-versus-host disease (cGVHD) in 2020. These milestones demonstrate Equillium's dedication to developing innovative solutions for patients in need.

Equillium Inc is primarily present in the United States and focuses on developing and commercializing products for severe autoimmune and inflammatory disorders.

Equillium Inc represents values of innovation, collaboration, and patient-centricity in its corporate philosophy. The company focuses on developing novel therapies to enhance the immune system and bring about better treatment outcomes for patients with severe autoimmune and inflammatory disorders. Equillium Inc strives to create value for its shareholders by advancing its pipeline of innovative biologic therapies that target the immune system. With a commitment to scientific excellence and a patient-first approach, Equillium Inc aims to make a meaningful impact on the lives of patients and become a leader in the field of immunotherapy.

Analyytikot asettavat tällä hetkellä Equillium-osakkeelle keskimääräisen tavoitehinnan 2,55 USD (mediaani: 2,55 USD), mikä merkitsee +79,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.

Equillium Analyytikkojen kursstavoitteet 2026

18 analyytikkoa arvioi tällä hetkellä Equillium-osaketta: 17 suosittaa ostoa, 1 pitoa ja 0 myyntiä.

Equillium Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Equillium-osake noteerataan hintaan 1,27 EUR (1,42 USD).

Equillium-osake (EQ) on listattuna 4 pörssissä, muun muassa: NASDAQ (EQ), London (0A4D.L), Frankfurt (0FY.F), München (0FY.MU).

Equillium Inc. is a pharmaceutical company that focuses on developing first-in-class immunotherapies for severe inflammatory and autoimmune diseases. Founded in 2017 in San Diego, California, the company aims to develop drugs that regulate the body's immune response to reduce inflammation and combat autoimmune diseases. Equillium's business model is based on the discovery of new compounds and their clinical development. The company has developed a special technology called EQUIP (Equillium Quantitative Insights into the Patient) that allows for the molecular measurement of the effectiveness of drugs against inflammation and autoimmune diseases. This involves using antibodies against specific target proteins that lead to the activation of inflammatory cells. These antibodies can then be quantified using a special method. One of Equillium Inc.'s key areas of focus is the clinical development of drugs targeting the regulation of the immune system. Addressing checkpoints that control the activity of immune regulatory cells and reducing the production of pro-inflammatory cytokines are important approaches. Equillium has a broad portfolio of development programs that relate to various diseases and indications. For example, the company is developing EQ001, a monoclonal antibody against the protein CD6, which plays a role in chronic inflammation and autoimmune diseases. EQ001 is currently being studied in clinical trials in patients with psoriasis, lupus, and uncontrolled asthma. Equillium's pipeline also includes EQ002, an antibody targeting two important pro-inflammatory cytokines that are relevant to severe inflammatory diseases, such as graft-versus-host disease after stem cell transplantation. In addition to clinical drug development, Equillium also offers services in the field of immune phenotyping. This involves developing methods to accurately characterize a patient's immune system and tailor therapeutic approaches accordingly. The company collaborates in this area with various research institutes and pharmaceutical companies. Overall, Equillium Inc.'s business model is characterized by a specialized focus on target identification and clinical development of immunotherapies. The company relies on a broad pipeline of drug candidates targeting various indications and further developed through the use of EQUIP technology. EQ001, which is already in Phase 2 development, shows promising results in the treatment of autoimmune diseases. Both therapy approaches and indications promise long-term growth potential.

Liikevaihtoa ei voida laskea Equillium:lle tällä hetkellä.

odotettu voitto Equillium on −12,53 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Equillium:n hinta-voitto-suhde (P/E) on tällä hetkellä −10,42. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Equillium-osakkeen arvostusta.

P/S-suhdetta ei voida laskea Equillium:lle tällä hetkellä.

Equillium:n Eulpool-laatuscore on 2/10.

Equillium:n ISIN on US29446K1060. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Equillium:n WKN on A2N7B3. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Equillium:n ticker on EQ. Tämä pörssinoteeraus käytetään Equillium-osakkeiden kauppaan pörssissä.